South Korea: OliX Pharmaceuticals concludes third party capital increase

Dong Ki Lee, founder and CEO, OliX Pharmaceuticals

Kosdaq-listed OliX Pharmaceuticals, a developer of RNAi therapeutics, has completed a capital raise to support its R&D activities and improve its financial structure. The paid-in capital increase totaled KRW57bn (US$45m) with about 3 million convertible preferred stocks. Eight local institutional investors, including KB Investment, IMM Investment, Company K Partners, Solidus Investment, Susung Asset Management, Welcome…

You must be a HMI Subscriber to view this content.

Subscribe Now »